versione pdf - Sistema Nazionale Linee Guida

Iperplasia prostatica benignametric parameters in patients with benign prostatichyperplasia. Br J Clin Pharmacol 2000;49:269-73.193 Ozbey I, Aksoy Y, Polat O, Bicgi O, Demirel A,Okyar G. Effects of doxazosin in men withbenign prostatic hyperplasia: urodynamic assessment.Int Urol Nephrol 1999;31:471-9.194 Os I, Stokke HP. Doxazosin GITS compared withdoxazosin standard and placebo in patients withmild hypertension. Blood Press 1999;8:184-91.195 Chung M, Vashi V, Puente J, Sweeney M, MeredithP. Clinical pharmacokinetics of doxazosin ina controlled-release gastrointestinal therapeuticsystem (GITS) formulation. Br J Clin Pharmacol1999;48:678-87.196 Schulman CC, Cortvirend J, Jonas U, LockTMTW, Vaage S, Speakman MJ on behalf of theEuropean Tamsulosin Study Group. Tamsulosin:3-year long-term efficacy and safety in patientswith lower urinary tract symptoms suggestive ofbenign prostatic obstruction: analysis of a European,multinational, multicenter, open-labelstudy. Eur Urol 1999;36:609-20.197 MacDiarmid SA, Emery RT, Ferguson SF,McGuirt-Franklin R, McIntyre WJ, Johnson DE. Arandomized double-blind study assessing 4 versus8 mg doxazosin for benign prostatic hyperplasia.J Urol 1999;162:1629-32.198 McNeill SA, Daruwala PD, Mitchell ID, ShearerMG, Hargreave TB. Sustained-release alfuzosinand trial without catheter after acute urinaryretention: a prospective, placebo-controlled. BJUInt 1999;84:622-7.199 Fawzy A, Hendry A, Cook E, Gonzalez F. Longterm(4 year) efficacy and tolerability of doxazosinfor the treatment of concurrent benign prostatichyperplasia and hypertension. Int J Urol1999;6:346-54.200 Narayan P, Tewari A for the United States 93-01Study Group. A second phase III multicenterplacebo controlled study of 2 dosages of modifiedrelease tamsulosin in patients with symptomsof benign prostatic hyperplasia. J Urol1998;160:1701-6.201 Kirby RS. Terazosin in benign prostatic hyperplasia:effects on blood pressure in normotensive andhypertensive men. Br J Urol 1998;82:373-9.202 Lepor H, Williford WO, Barry MJ, Haakenson C,Jones K. The impact of medical therapy on botherdue to symptoms, quality of life and global outcome,and factors predicting response. VeteransAffairs Cooperative Studies Benign ProstaticHyperplasia Study Group. J Urol 1998;160:1358-67.203 Debruyne FM, Jardin A, Colloi D, Resel L, WitjesWP, Delauche-Cavallier MC, et al. Sustainedreleasealfuzosin, finasteride and the combinationof both in the treatment of benign prostatichyperplasia. European ALFIN Study Group. EurUrol 1998;34:169-75.204 Lepor H. Long-term evaluation of tamsulosin inbenign prostatic hyperplasia: placebo-controlled,double-blind extension of phase III trial. TamsulosinInvestigator Group. Urology 1998;51:901-6.205 Lepor H for the Tamsulosin Investigator Group.Phase III multicenter placebo-controlled study oftamsulosin in benign prostatic hyperplasia. Urology1998;51:892-900.206 DeMey C, Michel MC, Mc Ewen J, Moreland T.A double-blind comparison of terazosin andtamsulosin on their differential effects on ambulatoryblood pressure and nocturnal ortostaticstress testing. Eur Urol 1998;33:481-8.207 Buzelin JM, Fonteyne E, Kontturri M, Witjes WP,Khan A. Comparison of tamsulosin with alfuzosinin the treatment of patients with lower urinarytract symptoms suggestive of bladder outletobstruction (symptomatic benign prostatic hyperplasia).Br J Urol 1997;80:597-605.208 Roehrborn CG, van Kerrebroek P, Nordling J.Safety and efficacy of alfuzosin 10 mg once-dailyin the treatment of lower urinary tract symptomsand clinical benign prostatic hyperplasia: apooled analysis of three double-blind, placebocontrolled studies. BJU Int 2003;92:257-61.209 Höfner K, Claes H, De Reijke TM, Folkestad B,Speakman MJ. Tamsulosin 0.4 mg once daily:effect on sexual function in patients with lowerurinary tract symptoms suggestive of benign prostaticobstruction. Eur Urol 1999;36:335-41.210 Schulman CC, Lock TMTW, Buzelin IM, BoeminghausF, Stephenson TP, et al. for the EuropeanTamsulosin Study Group. Long term use of tamsulosinto treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 2001;166:1358-63.211 Wilt TJ, Mac Donald R, Rutks I. Tamsulosin forbenign prostatic hyperplasia (Cochrane Review).In: The Cochrane Library, Issue 1, 2004. Chichester,UK: John Wiley & Sons, Ltd.212 Mann RD, Biswas P, Freemantle S, Pearce G,Wilton L. The pharmacovigilance of tamsulosin:event data on 12484 patients. BJU Int 2000;85:446-50.213 McConnell JD, Bruskewitz R, Walsh P, AndrioleG, Lieber M, Holtgrewe HL, et al. The effect offinasteride on the risk of acute urinary retentionand the need for surgical treatment among menwith benign prostatic hyperplasia. FinasterideLong-Term Efficacy and Safety Study Group. NEngl J Med 1998;338:557-63.214 Nickel JC, Fradet Y, Boake RC, Pommerville PJ,Perreault JP, Afridi SK, et al. Efficacy and safetyof finasteride therapy for benign prostatic hyperplasia:results of a 2-year randomized controlledtrial (the PROSPECT study). PROscar Safety PlusEfficacy Canadian Two year Study. CMAJ1996;155:1251-9.215 Marberger MJ. Long-term effects of finasteride inpatients with benign prostatic hyperplasia: adouble-blind, placebo-controlled, multicenterstudy. PROWESS Study Group.Urology 1998;51:677-86.216 Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD for FinasterideStudy Group.The effect of finasteride inmen with benign prostatic hyperplasia. J Urol2002;167:1102-7.Bibliografia essenziale43